Search research articles
Contact Us
Filters
Showing results (81-90 of 129) with videos related to
Page
of 13
Sort By:
Pigment Cell & Melanoma Research
|
June 24, 2026
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025
Andrew E Aplin, Katherina Alsina, Allison S Betof, et al.
European Urology Focus
|
February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy
Peter E Hall, Scott T C Shepherd, Janet Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
Teresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Cell Reports. Medicine
|
February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
James Larkin, Richard Marais, Nuria Porta, et al.
Journal for Immunotherapy of Cancer
|
December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Journal for Immunotherapy of Cancer
|
July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Nature Medicine
|
October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Takami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 129) with videos related to
Sort By:
Page
of 13
Pigment Cell & Melanoma Research
|
June 24, 2026
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025
Andrew E Aplin, Katherina Alsina, Allison S Betof, et al.
European Urology Focus
|
February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy
Peter E Hall, Scott T C Shepherd, Janet Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
Teresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Cell Reports. Medicine
|
February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
James Larkin, Richard Marais, Nuria Porta, et al.
Journal for Immunotherapy of Cancer
|
December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Journal for Immunotherapy of Cancer
|
July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Nature Medicine
|
October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Takami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, et al.
Page
of 13